Scarica l'app Stockscreener
23.23
4.97%
1.10
Dopo l'orario di chiusura:
22.88
-0.35
-1.51%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SRPT Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$22.13
Aprire:
$21.93
Volume 24 ore:
3.15M
Relative Volume:
1.06
Capitalizzazione di mercato:
$2.44B
Reddito:
$2.20B
Utile/perdita netta:
$-842.79M
Rapporto P/E:
-2.753
EPS:
-8.4382
Flusso di cassa netto:
$-332.39M
1 W Prestazione:
+7.15%
1M Prestazione:
+42.34%
6M Prestazione:
+3.94%
1 anno Prestazione:
-62.81%
Intervallo 1D:
$21.62
$23.29
Intervallo di 1 settimana:
$19.71
$23.29
Portata 52W:
$10.41
$64.80
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Nome
Sarepta Therapeutics Inc
Settore
Industria
Telefono
617-274-4000
Indirizzo
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
23.23 | 2.44B | 2.20B | -842.79M | -332.39M | -8.4382 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Equal Weight |
| 2025-12-09 | Iniziato | Wedbush | Outperform |
| 2025-11-05 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-09-22 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-29 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2025-07-29 | Iniziato | Bernstein | Mkt Perform |
| 2025-07-29 | Reiterato | H.C. Wainwright | Sell |
| 2025-07-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2025-07-29 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-07-28 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-07-25 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-07-24 | Iniziato | Citigroup | Sell |
| 2025-07-23 | Downgrade | BofA Securities | Neutral → Underperform |
| 2025-07-22 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-07-21 | Downgrade | Deutsche Bank | Buy → Hold |
| 2025-07-21 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | Downgrade | Mizuho | Outperform → Neutral |
| 2025-07-21 | Downgrade | Needham | Hold → Underperform |
| 2025-07-21 | Downgrade | UBS | Buy → Neutral |
| 2025-07-18 | Downgrade | Needham | Buy → Hold |
| 2025-06-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | Downgrade | TD Cowen | Buy → Hold |
| 2025-06-17 | Iniziato | Wolfe Research | Peer Perform |
| 2025-06-16 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-06-16 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | Downgrade | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-04-11 | Iniziato | Wells Fargo | Overweight |
| 2025-04-02 | Aggiornamento | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2024-11-27 | Reiterato | Needham | Buy |
| 2024-11-25 | Iniziato | H.C. Wainwright | Sell |
| 2024-11-07 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | Iniziato | Jefferies | Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-07-29 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | Downgrade | Citigroup | Buy → Neutral |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-05-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-01-31 | Iniziato | BMO Capital Markets | Outperform |
| 2023-12-13 | Ripresa | Citigroup | Buy |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-11-21 | Iniziato | Wedbush | Outperform |
| 2023-10-31 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-06-23 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-04-26 | Iniziato | SMBC Nikko | Outperform |
| 2023-04-04 | Iniziato | Citigroup | Buy |
| 2023-03-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | Reiterato | BTIG Research | Buy |
| 2022-12-16 | Aggiornamento | UBS | Neutral → Buy |
| 2022-04-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-01-05 | Reiterato | Needham | Buy |
| 2021-12-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-11-05 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-09-15 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-08-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-01-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-01-11 | Downgrade | UBS | Buy → Neutral |
| 2021-01-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Iniziato | Berenberg | Hold |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-08-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | Iniziato | Mizuho | Buy |
| 2019-11-01 | Iniziato | Guggenheim | Buy |
| 2019-08-21 | Reiterato | Needham | Buy |
| 2019-07-09 | Reiterato | Morgan Stanley | Overweight |
| 2019-07-01 | Reiterato | RBC Capital Mkts | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-11 | Reiterato | Credit Suisse | Outperform |
| 2018-10-12 | Iniziato | Bernstein | Outperform |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-26 | Reiterato | RBC Capital Mkts | Outperform |
| 2018-09-14 | Ripresa | BofA/Merrill | Buy |
| 2018-09-06 | Iniziato | Credit Suisse | Outperform |
| 2018-08-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | Reiterato | Robert W. Baird | Outperform |
| 2018-06-20 | Reiterato | Needham | Buy |
| 2018-06-19 | Reiterato | H.C. Wainwright | Buy |
Mostra tutto
Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie
Aberdeen Group Boosts Stake in Sarepta Therapeutics - National Today
Aberdeen Group plc Increases Stake in Sarepta Therapeutics, Inc. $SRPT - marketbeat.com
Why is Sarepta Therapeutics (SRPT) up 24.2% since last earnings report? - MSN
The Precedent: Federal Circuit Upholds Gene Therapy Host Cell Claims Under 35 U.S.C. § 101 in Regenxbio Inc., Et Al. v. Sarepta Therapeutics, Inc., Et Al. - JD Supra
SG Americas Securities Trims Sarepta Therapeutics Stake - National Today
SG Americas Securities LLC Lowers Holdings in Sarepta Therapeutics, Inc. $SRPT - marketbeat.com
Sarepta gets New Zealand approval for Huntington’s disease trial - Investing.com
Sarepta Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Wealth Enhancement Advisory Services LLC Acquires 62,981 Shares of Sarepta Therapeutics, Inc. $SRPT - marketbeat.com
Sarepta Therapeutics, Inc. (SRPT) Stock forecasts - Yahoo Finance UK
SRPT Stock Price, Quote & Chart | SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) - ChartMill
Sarepta Therapeutics, Inc. (SRPT) Stock Price, News, Quote & History - finance.yahoo.com
Sarepta Therapeutics, Inc. (SRPT) Stock Forecasts - finance.yahoo.com
Charcot-Marie-Tooth (CMT) Disease Market Size to Reach US$ - openPR.com
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Sarepta plans FDA filings seeking full approval for two DMD therapies - msn.com
Trend Review: How volatile is Sarepta Therapeutics Inc stock2026 Buyback Activity & Consistent Income Trade Ideas - baoquankhu1.vn
Sarepta to soon submit SNDAs for traditional approval for Duchenne treatments - msn.com
MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI’s 2026 Performance - Yahoo Finance
FDA Grants Platform Technology Tag to Sarepta's Gene Therapy Vector - MSN
Mirador Capital Partners Invests $3M in Sarepta Therapeutics - National Today
Mirador Capital Partners LP Invests $3.01 Million in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Massachusetts Biotech Co. Finds High-Potential Muscle Treatment Breakthrough - Streetwise Reports
Biotech Price Target Raised on Strong FSHD & DM1 siRNA Data - Streetwise Reports
Sarepta (SRPT) skyrockets 35% on Morgan Stanley PT hike, stellar trial results - msn.com
Gene Therapy And US Patent Eligibility Update: REGENXBIO, Inc. v. Sarepta Therapeutics, Inc. - MarketScreener
Sarepta Therapeutics Inc (SRPT) Stock Price & 30 Year Financial Data - GuruFocus
Why has Sarepta Therapeutics (SRPT) risen by 24.2% following its most recent earnings announcement? - Bitget
Nasdaq 100 Enters Correction As 30-Year Yields Near 5%: What's Moving Markets Friday? - Benzinga
Vanguard realigns reporting; reports 0 shares of Sarepta (SRPT) - Stock Titan
Why Is Sarepta Therapeutics (SRPT) Up 24.2% Since Last Earnings Report? - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Vertex Pharmaceuticals (VRTX) and Sarepta Therapeutics (SRPT) - The Globe and Mail
(SRPT) Volatility Zones as Tactical Triggers - Stock Traders Daily
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Tranche Update on Sarepta Therapeutics, Inc.'s Equity Buyback Plan announced on February 26, 2025. - marketscreener.com
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 8%Here's What Happened - MarketBeat
Rare Disease Biotech Sell Rating Maintained: Early Clinical Data Fails to Offset Flagship Drug Revenue Decline - Streetwise Reports
SRPT Stock Surges on Promising Early Results From siRNA Programs - The Globe and Mail
Sarepta TherapeuticsIt's Too Early To Get Excited About siRNA Data (NASDAQ:SRPT) - Seeking Alpha
SRPT: Citigroup Raises Price Target Amid Maintained 'Sell' Ratin - GuruFocus
Sarepta Therapeutics Is Maintained at Sell by Citigroup - Moomoo
Sarepta Therapeutics (NASDAQ:SRPT) Given New $13.00 Price Target at Citigroup - MarketBeat
Deutsche Bank Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Raises Target Price to $14 - Moomoo
Deutsche Bank Adjusts Price Target for Sarepta (SRPT) Amid Stock Rally - GuruFocus
A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $5 to $35 - Moomoo
Sarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock? - Yahoo Finance
Sarepta Therapeutics (SRPT) Retains 'Underperform' Rating by Nee - GuruFocus
Sarepta Therapeutics (NASDAQ:SRPT) Earns Underperform Rating from Needham & Company LLC - marketbeat.com
Which Is a Better Investment, Apellis Pharmaceuticals, Inc. or Sarepta Therapeutics, Inc. Stock? - AAII.com
Early-stage data allows Sarepta to bounce back - The Pharma Letter
Deutsche Bank Raises Price Target on Sarepta Therapeutics to $14 From $12, Keeps Sell Rating - marketscreener.com
Sarepta Therapeutics Inc Azioni (SRPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):